NASDAQ:MGX Metagenomi (MGX) Stock Price, News & Analysis → Bill Clinton Backing Biden Replacement??? (From The Freeport Society) (Ad) Free MGX Stock Alerts $6.54 -0.01 (-0.15%) (As of 05/14/2024 ET) Add Compare Share Share Today's Range$6.50▼$6.7850-Day Range$6.17▼$12.0052-Week Range$5.50▼$12.74Volume92,536 shsAverage Volume154,349 shsMarket Capitalization$245.05 millionP/E RatioN/ADividend YieldN/APrice Target$17.83 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsSocial Media Get Metagenomi alerts: Email Address Ad Banyan Hill PublishingTrump’s Former Wingman Bets Big on AIOne of his AI company’s earliest investors was the CIA’s venture capital arm called In-Q-Tel … named after Q, the fictional character who makes gadgets for James Bond. Soon, an alphabet soup of 30 government agencies would entrust the company with their most sensitive information.Get the full story here. About Metagenomi Stock (NASDAQ:MGX)Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.Read More MGX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MGX Stock News HeadlinesMay 15 at 2:30 AM | markets.businessinsider.comBuy Rating Affirmed for Metagenomi Amidst Strong Financials and Promising Gene Editing BreakthroughsMay 15 at 12:06 AM | investorplace.comMGX Stock Earnings: Metagenomi Misses EPS, Beats Revenue for Q1 2024May 14 at 9:29 PM | finance.yahoo.comMetagenomi, Inc. (MGX)May 14 at 4:05 PM | globenewswire.comMetagenomi Presents Data at Scientific Conferences and First Quarter 2024 Financial ResultsMay 9, 2024 | americanbankingnews.comMetagenomi, Inc. Expected to Earn Q1 2024 Earnings of ($1.20) Per Share (NASDAQ:MGX)May 8, 2024 | msn.comHC Wainwright & Co. Initiates Coverage of Metagenomi (MGX) with Buy RecommendationMay 8, 2024 | americanbankingnews.comMetagenomi (NASDAQ:MGX) Now Covered by Analysts at HC WainwrightMay 6, 2024 | americanbankingnews.comMetagenomi (NASDAQ:MGX) Lowered to "Neutral" at JPMorgan Chase & Co.May 4, 2024 | msn.comJ.P. Morgan downgrades Metagenomi over Moderna deal terminationMay 2, 2024 | markets.businessinsider.comAnalyst Maintains ‘Buy’ Rating on Metagenomi Amidst New Opportunities Post-Moderna Partnership TerminationMay 2, 2024 | investorplace.com3 Gene Editing Stocks with the Potential to Make You an Overnight MillionaireMay 1, 2024 | globenewswire.comMetagenomi to regain full development rights to its wholly-owned base editing and RIGS systemsApril 8, 2024 | globenewswire.comMetagenomi to Present at Upcoming Scientific MeetingsApril 3, 2024 | fool.comMetagenomi (NASDAQ: MGX)April 2, 2024 | morningstar.comMetagenomi Inc MGXMarch 29, 2024 | markets.businessinsider.comMetagenomi, Inc.: Strong Buy Rating on Robust Hemophilia Program and Strategic PartnershipsMarch 29, 2024 | markets.businessinsider.comMetagenomi, Inc.: Strong Buy Rating on Promising Pipeline and Solid Financial PositioningMarch 28, 2024 | finanznachrichten.deMetagenomi, Inc.: Metagenomi Reports Business Updates and Full Year 2023 Financial ResultsMarch 27, 2024 | msn.comMetagenomi reports FY resultsMarch 27, 2024 | globenewswire.comMetagenomi Reports Business Updates and Full Year 2023 Financial ResultsFebruary 29, 2024 | globenewswire.comMetagenomi to Participate in the 44th Annual Cowen Healthcare ConferenceFebruary 19, 2024 | fool.comThis Biotech IPO Stock Just Took a Tumble, But Don't Give Up on It YetFebruary 18, 2024 | 247wallst.comInsider Buying: Taking a Controlling Stake in a Struggling Retailer?February 13, 2024 | globenewswire.comMetagenomi Announces Closing of Initial Public OfferingFebruary 9, 2024 | reuters.comModerna, Bayer-backed Metagenomi stock drops 32% on Nasdaq debutSee More Headlines Receive MGX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Metagenomi and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today5/15/2024Next Earnings (Estimated)6/26/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:MGX Previous SymbolNASDAQ:MGX CUSIPN/A CIK1785279 Webwww.metagenomi.co Phone510-871-4880FaxN/AEmployees236Year FoundedN/APrice Target and Rating Average Stock Price Target$17.83 High Stock Price Target$25.00 Low Stock Price Target$6.00 Potential Upside/Downside+172.7%Consensus RatingModerate Buy Rating Score (0-4)2.86 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio4.04 Quick Ratio4.04 Sales & Book Value Annual Sales$44.76 million Price / Sales5.47 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares37,470,000Free FloatN/AMarket Cap$245.05 million OptionableN/A BetaN/A (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesDr. Brian Charles Thomas Ph.D. (Age 55)Co-Founder, CEO & Chairman of the Board Comp: $859.34kDr. Jian Irish M.B.A. (Age 60)Ph.D., President, COO & Director Comp: $729.82kDr. Sarah B. Noonberg M.D. (Age 56)Ph.D., Chief Medical Officer Comp: $591.49kDr. Jak Knowles M.D.Co-Founder & Member of Scientific Advisory BoardMs. Pamela M. Wapnick M.B.A. (Age 58)Chief Financial Officer Dr. Luis G. Borges Ph.D. (Age 62)Chief Scientific Officer More ExecutivesKey CompetitorsFennec PharmaceuticalsNASDAQ:FENCMonte Rosa TherapeuticsNASDAQ:GLUEPoseida TherapeuticsNASDAQ:PSTXSutro BiopharmaNASDAQ:STROCoherus BioSciencesNASDAQ:CHRSView All CompetitorsInsiders & InstitutionsHhlr Advisors LTD.Bought 777,768 shares on 5/15/2024Ownership: 2.076%Altitude Crest Partners Inc.Bought 133,333 shares on 5/15/2024Ownership: 0.356%Vanguard Group Inc.Bought 179,547 shares on 5/10/2024Ownership: 0.479%Resolute Advisors LLCBought 10,000 shares on 5/10/2024Ownership: 0.027%Holdings A/S NovoBought 800,000 shares on 2/13/2024Total: $12 M ($15.00/share)View All Insider TransactionsView All Institutional Transactions MGX Stock Analysis - Frequently Asked Questions Should I buy or sell Metagenomi stock right now? 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Metagenomi in the last year. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" MGX shares. View MGX analyst ratings or view top-rated stocks. What is Metagenomi's stock price target for 2024? 7 brokerages have issued 1-year price objectives for Metagenomi's stock. Their MGX share price targets range from $6.00 to $25.00. On average, they anticipate the company's share price to reach $17.83 in the next year. This suggests a possible upside of 172.7% from the stock's current price. View analysts price targets for MGX or view top-rated stocks among Wall Street analysts. How have MGX shares performed in 2024? Metagenomi's stock was trading at $10.31 at the beginning of 2024. Since then, MGX stock has decreased by 36.6% and is now trading at $6.54. View the best growth stocks for 2024 here. When is Metagenomi's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, June 26th 2024. View our MGX earnings forecast. When did Metagenomi IPO? Metagenomi (MGX) raised $94 million in an initial public offering on Friday, February 9th 2024. The company issued 6,250,000 shares at a price of $15.00 per share. When did the company's quiet period expire? Metagenomi's quiet period expired on Wednesday, March 20th. Metagenomi had issued 6,250,000 shares in its public offering on February 9th. The total size of the offering was $93,750,000 based on an initial share price of $15.00. During the company's quiet period, insiders and underwriters involved in the IPO were prevented from issuing any research reports for the company because of SEC regulations. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company. Who are Metagenomi's major shareholders? Metagenomi's stock is owned by a variety of institutional and retail investors. Top institutional investors include Hhlr Advisors LTD. (2.08%), Vanguard Group Inc. (0.48%), Altitude Crest Partners Inc. (0.36%) and Resolute Advisors LLC (0.03%). View institutional ownership trends. How do I buy shares of Metagenomi? Shares of MGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:MGX) was last updated on 5/15/2024 by MarketBeat.com Staff From Our PartnersThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldWith revenue forecasted to grow dramatically in 2024 and beyond, this company should be on your radarStocks NewsCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersCharles Payne Demystifies OptionsUnstoppable ProsperityThe A.I. story nobody is telling you (Read ASAP)TradeSmith Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Metagenomi, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.